Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Kimberly Whelan M.D.
Professor
Close
E-mail
kifowler@uab.edu
Links
Provider Directory
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Kimberly Whelan M.D.
Professor
Positions
Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
Publications
Research
Teaching
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2020
Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features
.
Pediatric Blood and Cancer
. 67.
2020
2019
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
.
Scientific Reports
. 9.
2019
2019
Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma
.
Journal of Pediatric Surgery
. 54:2117-2119.
2019
2019
A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency
.
Pediatric Blood and Cancer
. 66.
2019
2019
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival
.
Journal of Pediatric Surgery
. 54:1206-1213.
2019
2019
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma
.
Translational Oncology
. 12:200-208.
2019
2019
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor
.
Oncotarget
. 10:5534-5548.
2019
2018
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
.
Oncotarget
. 9:22665-22679.
2018
2018
Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report.
.
Neuro-Oncology
. 20:132-142.
2018
2018
Adolescent and young adult oncology, version 2.2018: Clinical practice guidelines in oncology
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 16:66-97.
2018
2018
Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.
2018
2017
Benefit Finding and Quality of Life in Caregivers of Childhood Cancer Survivors
.
Cancer Nursing
. 40:E28-E37.
2017
2017
Inferior outcomes for black children with high risk acute lymphoblastic leukemia and the impact of socioeconomic variables
.
Pediatric Blood and Cancer
. 64:267-274.
2017
2017
Demographic, medical, and psychosocial predictors of benefit finding among caregivers of childhood cancer survivors
2017
2015
Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: A report from the Childhood Cancer Survivor Study
.
Cancer
. 121:1856-1863.
2015
2014
Barriers to the Use of Psychosocial Support Services Among Adolescent and Young Adult Survivors of Pediatric Cancer.
.
Journal of Adolescent and Young Adult Oncology
. 3:112-116.
2014
2014
Adolescent and young adult oncology, version 2.2014.
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 12:21-32.
2014
2014
Adolescent and young adult oncology, version 2.2014: Featured updates to the NCCN guidelines
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 12:21-32.
2014
2014
Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors
.
Fertility and Sterility
. 101:227-231.
2014
2013
Cognitive influences as mediators of family and peer support for pediatric cancer survivors' physical activity
2013
2012
Adolescent and young adult oncology clinical practice guidelines in oncology
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 10:1112-1150.
2012
2012
Toward a safer cure for low-risk Hodgkin lymphoma in children
.
Journal of the American Medical Association
. 307:2639-2641.
2012
2012
Social, demographic, and medical influences on physical activity in child and adolescent cancer survivors
.
Journal of Pediatric Psychology
. 37:198-208.
2012
2011
Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study
.
Pediatric Blood and Cancer
. 57:126-134.
2011
2010
Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study
.
Pediatric Blood and Cancer
. 54:103-109.
2010
2009
Predictors of inactive lifestyle among adult survivors of childhood cancer
.
Cancer
. 115:1984-1994.
2009
2006
Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report.
.
Journal of Clinical Oncology
. 24:9006.
2006
Chapter
Filter
Year
Title
Altmetric
2018
Epidemiology of Childhood Cancer
. 1-20.
2018
Research
Principal Investigator On
Childhood Cancer Survivor Study
awarded by
St. Jude Children's Research Hospital
Childhood Cancer Survivor Study
awarded by
St. Jude Children's Research Hospital
Hyundai Hope on Wheels Impact Grant
awarded by
HYUNDAI HOPE ON WHEELS
MCC 18613, Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20339 Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
Investigator On
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
awarded by
CHILDREN'S ONCOLOGY GROUP
AAML 1031 - Bayer
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION
awarded by
CHILDREN'S ONCOLOGY GROUP
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of y-Secretase Inhibitor, Nirogacestat (PF03084014:IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Adaptive Immunity and Persistent SARS-CoV-2 Replication
awarded by
National Cancer Institute/NIH/DHHS
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CCOP Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase II Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase ll Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Cookies for Kids' Cancer Phase 1 Supplemental
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia
awarded by
Duke University
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
NIH COG Phase I Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors
awarded by
University of Wisconsin-Milwaukee
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
PEPN2112- A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Private Grant
awarded by
MILLENNIUM PHARMACEUTICALS, INC.
Private Grant
awarded by
UNITED THERAPEUTICS CORPORATION
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
Bayer AG
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
EISAI, INC.
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Project Everychild APEC14B1
awarded by
CHILDREN'S ONCOLOGY GROUP
Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma
awarded by
NEW YORK MEDICAL COLLEGE
St. Baldrick's Foundation Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
St. Baldricks Fdn Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Transforming Pediatric Oncology Healthcare Through Family Navigation
awarded by
UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Teaching
Teaching Activities
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2019)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017)
52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2021)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2021)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2021)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2021)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2022)
52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2023)
PCL2225 - HEMATOLOGY / ONCOLOGY (Fall Term 2008)
PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2009)
PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2010)
PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2011)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2013)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2014)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2016)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2017)
PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2018)
Background
Education And Training
Vanderbilt University Medical Center, Residency
UAB Hospital, Postdoctoral Fellowship
Doctor of Medicine,
University of South Carolina System : Columbia
2000
Contact
Full Name
Kimberly
Whelan